Spero Therapeutics Inc logo

Spero Therapeutics Inc

NEW
NAS:SPRO (USA)  
$ 0.74 -0.023 (-2.96%) 11:21 AM EST
At Loss
P/B:
0.88
Market Cap:
$ 40.55M
Enterprise V:
$ -6.80M
Volume:
120.15K
Avg Vol (2M):
163.30K
Trade In:
What is a stock summary page? Click here for an overview.
Volume:
120.15K
At Loss
Avg Vol (2M):
163.30K

Business Description

Description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Name Current Vs Industry Vs History
Cash-To-Debt 11.44
Equity-to-Asset 0.42
Debt-to-Equity 0.1
Debt-to-EBITDA -0.06
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.7
Distress
Grey
Safe
Beneish M-Score 11
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year Revenue Growth Rate 433.9
3-Year FCF Growth Rate 45.5
3-Year Book Growth Rate -23.5

Liquidity Ratio

Name Current Vs Industry Vs History

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -21.9
Shareholder Yield % 2.77

Financials (Next Earnings Date:2025-05-15 Est.)

SPRO's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:SPRO

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Spero Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 27.396
EPS (TTM) ($) -1.27
Beta -0.25
3-Year Sharpe Ratio -0.29
3-Year Sortino Ratio -0.51
Volatility % 26.84
14-Day RSI 43.47
14-Day ATR ($) 0.048599
20-Day SMA ($) 0.78984
12-1 Month Momentum % -54.91
52-Week Range ($) 0.7 - 1.81
Shares Outstanding (Mil) 54.52

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Spero Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Spero Therapeutics Inc Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Spero Therapeutics Inc Frequently Asked Questions

What is Spero Therapeutics Inc(SPRO)'s stock price today?
The current price of SPRO is $0.74. The 52 week high of SPRO is $1.81 and 52 week low is $0.70.
When is next earnings date of Spero Therapeutics Inc(SPRO)?
The next earnings date of Spero Therapeutics Inc(SPRO) is 2025-05-15 Est..
Does Spero Therapeutics Inc(SPRO) pay dividends? If so, how much?
Spero Therapeutics Inc(SPRO) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1